Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3

Background: Previous analyses from the PALOMA-2 and PALOMA-3 studies showed that palbociclib (PAL) plus endocrine therapy (ET) prolongs time to first subsequent chemotherapy (TTC) versus placebo (PBO) plus ET in the overall population of patients with hormone receptor‒positive/human epidermal growth...

Full description

Bibliographic Details
Main Authors: Hope S. Rugo, Seock-Ah Im, Anil A. Joy, Yaroslav Shparyk, Janice M. Walshe, Bethany Sleckman, Sherene Loi, Kathy Puyana Theall, Sindy Kim, Xin Huang, Eustratios Bananis, Reshma Mahtani, Richard S. Finn, Véronique Diéras
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Breast
Subjects:
Advanced breast cancer
Chemotherapy
Palbociclib
Progression-free survival
Safety
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977622001886

Internet

http://www.sciencedirect.com/science/article/pii/S0960977622001886

Similar Items